JP6364478B2 - ドネペジル遊離塩基含有フィルム製剤及びその製造方法 - Google Patents
ドネペジル遊離塩基含有フィルム製剤及びその製造方法 Download PDFInfo
- Publication number
- JP6364478B2 JP6364478B2 JP2016512844A JP2016512844A JP6364478B2 JP 6364478 B2 JP6364478 B2 JP 6364478B2 JP 2016512844 A JP2016512844 A JP 2016512844A JP 2016512844 A JP2016512844 A JP 2016512844A JP 6364478 B2 JP6364478 B2 JP 6364478B2
- Authority
- JP
- Japan
- Prior art keywords
- free base
- film
- donepezil
- donepezil free
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims description 128
- 229960003530 donepezil Drugs 0.000 title claims description 64
- 239000012458 free base Substances 0.000 title claims description 52
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title description 3
- 239000006185 dispersion Substances 0.000 claims description 38
- 239000003381 stabilizer Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000004373 Pullulan Substances 0.000 claims description 4
- 229920001218 Pullulan Polymers 0.000 claims description 4
- 235000019423 pullulan Nutrition 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 11
- 229960003135 donepezil hydrochloride Drugs 0.000 description 8
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000004014 plasticizer Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 230000009967 tasteless effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940124717 Alzheimer's therapeutics Drugs 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
[ドネペジル遊離塩基含有フィルムの製造]
ドネペジル遊離塩基含有フィルム製剤は次のように製造した。精製水に可塑剤(plasticizer)、添加剤(additive)、甘味剤(sweeting agent)、界面活性剤(surfactant)及び分散安定化剤(dispersing agent)を添加した後、撹拌して溶解または分散させ、それにドネペジル遊離塩基を添加した。その後、ホモジナイザー(Ultra turrax T−25、IKA)を使用して均質化した。それに高分子を添加し、同じホモジナイザーを使用してさらに均質化した。それに香料(flavor)を添加した後、前記ドネペジル遊離塩基が分散した高分子液と撹拌して混合した。次いで、真空条件でフィルム製造液内のガスを除去し、室温まで冷却させた後、PETフィルム上に適当な厚さでコーティングした。その後、80℃で乾燥してドネペジル遊離塩基を含むフィルム製剤を製造した。
[実施例1〜16.添加する分散安定化剤の種類別分散安定度の比較]
上記「ドネペジル遊離塩基含有フィルム製剤の製造」方法と同様にしてフィルムを製造した。ただし、フィルムに含まれる成分及び含量を下記表1のように異ならせてフィルムを製造し、フィルム内のドネペジル遊離塩基の含量を分析して分散安定度を測定した結果をRSD%(相対標準偏差)で示した。
Claims (3)
- ドネペジル遊離塩基の分散のための分散安定化剤としてのポリビニルアルコールと、
フィルム形成のための高分子としてのプルラン、ヒドロキシプロピルセルロース(HPC)、又は、これらの混合物と、を含むドネペジル遊離塩基含有フィルムであって、
活性成分としてのドネペジル遊離塩基が前記ドネペジル遊離塩基含有フィルムに分散されていることを特徴とするドネペジル遊離塩基含有フィルム。 - 前記ポリビニルアルコールは乾燥したフィルムの総重量を基準に0.1〜50重量%で含まれることを特徴とする請求項1に記載のフィルム。
- 活性成分としてドネペジル遊離塩基を分散させた高分子溶液を乾燥して製造するドネペジル遊離塩基含有フィルムの製造方法であって、
高分子は、プルラン、ヒドロキシプロピルセルロース(HPC)、又は、これらの混合物であり、前記高分子溶液は、ドネペジル遊離塩基の分散のための分散安定化剤としてのポリビニルアルコールを含む、ことを特徴とするドネペジル遊離塩基含有フィルムの製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130053355 | 2013-05-10 | ||
KR10-2013-0053355 | 2013-05-10 | ||
PCT/KR2014/004218 WO2014182138A1 (ko) | 2013-05-10 | 2014-05-12 | 도네페질 유리염기 함유 필름 제제 및 이의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016518405A JP2016518405A (ja) | 2016-06-23 |
JP6364478B2 true JP6364478B2 (ja) | 2018-07-25 |
Family
ID=51867531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016512844A Expired - Fee Related JP6364478B2 (ja) | 2013-05-10 | 2014-05-12 | ドネペジル遊離塩基含有フィルム製剤及びその製造方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160081990A1 (ja) |
EP (1) | EP2995301B1 (ja) |
JP (1) | JP6364478B2 (ja) |
KR (1) | KR102305037B1 (ja) |
CN (1) | CN105324111B (ja) |
BR (1) | BR112015028291A2 (ja) |
MX (1) | MX370064B (ja) |
RU (1) | RU2671487C2 (ja) |
TW (1) | TWI671085B (ja) |
WO (1) | WO2014182138A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9301948B2 (en) * | 2013-07-31 | 2016-04-05 | Intelgenx Corp. | Instantly wettable oral film dosage form without surfactant or polyalcohol |
KR101791342B1 (ko) * | 2016-05-31 | 2017-10-30 | 충북대학교 산학협력단 | 도네페질 유리염기를 함유하는 맛-차폐 복합입자 및 이를 포함한 경구투여 제형 |
CN107375945B (zh) * | 2017-08-29 | 2020-10-13 | 沈阳药科大学 | 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂 |
DE102017127452A1 (de) * | 2017-11-21 | 2019-05-23 | Lts Lohmann Therapie-Systeme Ag | Wasserlösliche Polymerklebschichten |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0739464B2 (ja) | 1987-04-22 | 1995-05-01 | ダイセル化学工業株式会社 | 成形用樹脂型剤 |
WO2003030882A1 (en) * | 2001-10-12 | 2003-04-17 | Kosmos Pharma | Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform |
AR051397A1 (es) * | 2004-10-21 | 2007-01-10 | Novartis Ag | Composicion farmaceutica |
KR100691608B1 (ko) * | 2005-02-21 | 2007-03-12 | (주)나노하이브리드 | 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법 |
IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
AU2007304425B2 (en) * | 2006-10-02 | 2013-12-05 | Spepharma Ag | Non-mucoadhesive film dosage forms |
CA2670991A1 (en) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Percutaneously absorbable preparation comprising donepezil |
AU2008304033B2 (en) * | 2007-09-28 | 2014-05-01 | Ctc Bio, Inc. | Pharmaceutical composition containing esomeprazole |
WO2009043588A2 (en) * | 2007-10-02 | 2009-04-09 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Ph regulating antibacterial films for the oral or vaginal cavity |
WO2010146601A1 (en) * | 2009-06-15 | 2010-12-23 | Unijules Life Sciences Ltd | Rapid dissolvable oral film for delivering herbal extract/s with or without other pharmaceutically active agents |
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
US20110237563A1 (en) * | 2010-03-23 | 2011-09-29 | Dominique Costantini | Fast dissolving drug delivery systems |
TWI433904B (zh) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
MY163288A (en) * | 2011-02-11 | 2017-08-30 | Ctc Bio Inc | Sildenafil-free base-containing film preparation and method for producing same |
KR101239150B1 (ko) * | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
CN103083284B (zh) * | 2013-02-06 | 2014-08-06 | 上海现代药物制剂工程研究中心有限公司 | 膜状制剂及其制备方法 |
-
2014
- 2014-05-12 CN CN201480029825.4A patent/CN105324111B/zh not_active Expired - Fee Related
- 2014-05-12 BR BR112015028291A patent/BR112015028291A2/pt active Search and Examination
- 2014-05-12 US US14/890,247 patent/US20160081990A1/en not_active Abandoned
- 2014-05-12 EP EP14794522.4A patent/EP2995301B1/en active Active
- 2014-05-12 WO PCT/KR2014/004218 patent/WO2014182138A1/ko active Application Filing
- 2014-05-12 JP JP2016512844A patent/JP6364478B2/ja not_active Expired - Fee Related
- 2014-05-12 MX MX2015015377A patent/MX370064B/es active IP Right Grant
- 2014-05-12 KR KR1020157031701A patent/KR102305037B1/ko active IP Right Grant
- 2014-05-12 RU RU2015152803A patent/RU2671487C2/ru active
- 2014-05-12 TW TW103116797A patent/TWI671085B/zh active
Also Published As
Publication number | Publication date |
---|---|
KR20160005035A (ko) | 2016-01-13 |
CN105324111A (zh) | 2016-02-10 |
EP2995301A1 (en) | 2016-03-16 |
RU2015152803A (ru) | 2017-06-16 |
KR102305037B1 (ko) | 2021-09-24 |
EP2995301B1 (en) | 2019-08-07 |
BR112015028291A2 (pt) | 2017-07-25 |
CN105324111B (zh) | 2019-06-28 |
US20160081990A1 (en) | 2016-03-24 |
MX2015015377A (es) | 2016-05-31 |
TW201511781A (zh) | 2015-04-01 |
JP2016518405A (ja) | 2016-06-23 |
RU2671487C2 (ru) | 2018-11-01 |
TWI671085B (zh) | 2019-09-11 |
WO2014182138A1 (ko) | 2014-11-13 |
MX370064B (es) | 2019-11-29 |
EP2995301A4 (en) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7347474B2 (ja) | 経口フィルム製剤 | |
JP5973467B2 (ja) | シルデナフィル遊離塩基含有フィルム製剤及びその製造方法 | |
JP6364478B2 (ja) | ドネペジル遊離塩基含有フィルム製剤及びその製造方法 | |
EP3069716A1 (en) | Orally disintegrating porous film comprising pharmacological active ingredient and method for preparing same | |
JP6470257B2 (ja) | 分散安定化剤としてポリエチレングリコール系高分子及び/またはビニルピロリドン系高分子を含むタダラフィル遊離塩基含有フィルム剤形 | |
JP2010519325A (ja) | 活性物質の経口投与のための速崩壊性単層膜 | |
JP2012522742A (ja) | 7−[4−[4−(2,3−ジクロロフェニル)ピペラジン−1−イル]ブトキシ]−3,4−ジヒドロ−1h−キノリン−2−オン塩基またはその塩もしくは水和物を含む経口フィルム | |
JP2013253038A (ja) | 口腔内溶解型フィルム製剤 | |
JPWO2017170854A1 (ja) | 有効成分の化学的安定性に優れたフィルムコーティング錠 | |
CN104940173A (zh) | 可溶性芬太尼及其衍生物口颊膜制剂及其制备方法 | |
JP5466379B2 (ja) | フィルム状製剤及びフィルム状製剤の製造方法 | |
JP2024507452A (ja) | 高配合の経口フィルム製剤 | |
JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
JP2020075874A (ja) | ルビプロストン含有フィルム状医薬組成物 | |
CN114053206A (zh) | 一种药物漂浮制剂及其制备方法 | |
JP2020193229A5 (ja) | ||
KR20190085203A (ko) | 사르포그릴레이트를 포함하는 지속 방출 제제 | |
JP2018184360A (ja) | 経口投与用の腸溶性徐放性製剤 | |
JPWO2016117642A1 (ja) | フィルム製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180702 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6364478 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |